Tag - IDYA

Markets

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

Stifel upgraded IDEADYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” and raised its price target to $24 from $18 following additional darovasertib data in uveal melanoma, which revealed an improved mPFS in first-line...

April 24, 2023

Markets

Stifel cuts IDEAYA to hold on skepticism of MAT2A cancer program

Stifel downgraded IDEAYA Biosciences (NASDAQ:IDYA) to “hold” from “buy” and reduced its price target to $13 from $16 “on the belief that it’s difficult to gain high conviction in the MTAP/MAT2A thesis (we ascribe...

August 15, 2022

Markets

Stifel ups IDEAYA Biosciences to buy; PT cut to $20

Stifel upgraded IDEAYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” but cut its price target to $20 from $27, saying the risk/reward around the company’s IDE397 drug candidate is favorable with the stock in the mid-to...

March 10, 2022

Markets

HCW starts IDEAYA Biosciences at buy; PT $13

H.C. Wainwright launched coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a “buy” rating and $13 price target. The stock closed at $3.59 on April 3. Analyst Edward White writes that IDE196 is the company’s potent...

April 6, 2020

Tag - IDYA

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

Stifel cuts IDEAYA to hold on skepticism of MAT2A cancer program

Stifel ups IDEAYA Biosciences to buy; PT cut to $20

HCW starts IDEAYA Biosciences at buy; PT $13

General

More